| Schedule of Outstanding Warrants to Purchase Common Stock Issued to Stockholders |
As of June 30, 2026, the Company had the following outstanding warrants to purchase Common Stock issued to stockholders: | Warrant | | Issuance Date | | Expiration Date | | Exercise Price Per Share | | | Number of Shares of Common Stock Underlying Warrants | | | | | | | | | | | | | | | 2021 Registered Direct Offering Warrants | | July 28, 2021 | | January 28, 2027 | | | 950.00 | | | | 14,808 | | | Merger Warrants | | March 15, 2024 | | January 28, 2027 | | | 950.00 | | | | 11,404 | | | Private Placement Warrants | | March 15, 2024 | | July 9, 2026 | | | 43.91 | | | | 203,444 | | | Registered Pre-Funded Warrants | | February 25, 2025 | | April 21, 2030 | | | 0.0019 | | | | 42,381 | | | Private Pre-Funded Warrants | | February 25, 2025 | | April 21, 2030 | | | 0.0019 | | | | 46,232 | | | Common Warrants | | February 25, 2025 | | April 21, 2030 | | | 17.68 | | | | 312,503 | | | Inducement Warrants | | February 25, 2025 | | April 21, 2030 | | | 17.68 | | | | 366,087 | | | A&R Warrants | | February 25, 2025 | | April 21, 2030 | | | 0.0019 | | | | 25,119 | | | | | | | | | | | | | | 1,021,978 | | As of June 30, 2026, the Company had the following outstanding compensation related warrants to purchase Common Stock: | Warrant | | Issuance Date | | Expiration Date | | Exercise Price Per Share | | | Number of Shares of Common Stock Underlying Warrants | | | | | | | | | | | | | | | Private Warrants issued to scientific founders* | | November 27, 2017 | | - | | | - | | | | 16 | | | Landlord Warrants | | March 15, 2024 | | January 28, 2027 | | | 950.00 | | | | 1,316 | | | Agents Warrants | | March 15, 2024 | | July 9, 2026 | | | 43.91 | | | | 50,126 | | | January 2026 private placement agent warrants | | January 13, 2026 | | January 12, 2031 | | | 2.50 | | | | 99,000 | | | | | | | | | | | | | | 150,458 | | | * | In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. |
|
| Schedule of Options Granted to Purchase the Company’s Common Stock Under the Company’s Share Option Plans |
A summary of options granted to purchase the Company’s Common Stock under the Company’s share option plans is as follows: | | | For the Six Months Ended June 30, 2026 | | | | | Number of Options | | | Weighted Average Exercise Price | | | Aggregate Intrinsic Value | | | Outstanding at the beginning of period | | | 150,387 | | | $ | 51.94 | | | $ | - | | | Granted | | | - | | | | - | | | | - | | | Forfeited | | | 148,675 | | | | 36.68 | | | | - | | | Expired | | | 1,712 | | | | 32.53 | | | | - | | | Exercised | | | - | | | | - | | | | - | | | Outstanding at the end of period | | | - | | | | - | | | $ | - | | | Exercisable at end of period | | | - | | | | - | | | | | | | Weighted average remaining contractual life – years as of June 30, 2026 | | | - | | | | | | | | | |
|
| Schedule of Stock-Based Payment Expenses |
The following table sets forth the total stock-based payment expenses resulting from options, RSUs and warrants granted, included in the consolidated statements of operations: | | | Three Months Ended June 30, | | | Six Months Ended June 30, | | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | | | | | | | | | | | | | | | Research and development expenses, net | | | - | | | | 279 | | | | (647 | ) | | | 467 | | | General and administrative | | | 3,988 | | | | 417 | | | | 2,707 | | | | 888 | | | | | | 3,988 | | | | 696 | | | | 2,060 | | | | 1,355 | |
|